Unfortunately, the Greek Ministry of Education and Religious Affairs changes the list with the disability codes by adding or deleting disabilities and diseases every year.
NKUA Code | Short description | Greek Ministry of Education and Religious Affairs Code for the acad. year 2021-2022 |
---|---|---|
01 | Blind | 01 Blind |
02 | Low visual acuity | 02 Low visual acuity (with a disability degree of at least 80%) |
03 | Deaf | 03 Deaf |
04 | Deaf-mute | 04 Deaf-mute |
05 | Mediterranean anemia/ Thalassemia major | 05 Persons suffering from congenital hemolytic anemias undergoing blood transfusions or having severe clinical manifestations deemed disabled with a degree of disability of at least 67% (Mediterranean anemia/Beta thalassemia/Thalassemia major, sickle cell anemia, micro-sickle cell anemia, persons suffering from Mediterranean anemia/ Beta thalassemia/Thalassemia major undergoing multiple blood transfusions, hemolytic anemia due to pyruvate kinase deficiency, Diamond Blackfan anemia) |
06 | Sickle cell anemia | 05 Persons suffering from congenital hemolytic anemias undergoing blood transfusions or having severe clinical manifestations deemed disabled with a degree of disability of at least 67% (Mediterranean anemia/Beta thalassemia/Thalassemia major, sickle cell anemia, micro-sickle cell anemia, persons suffering from Mediterranean anemia/ Beta thalassemia/Thalassemia major undergoing multiple blood transfusions, hemolytic anemia due to pyruvate kinase deficiency, Diamond Blackfan anemia) |
07 | Micro-sickle cell anemia | 05 Persons suffering from congenital hemolytic anemias undergoing blood transfusions or having severe clinical manifestations deemed disabled with a degree of disability of at least 67% (Mediterranean anemia/Beta thalassemia/Thalassemia major, sickle cell anemia, micro-sickle cell anemia, persons suffering from Mediterranean anemia/ Beta thalassemia/Thalassemia major undergoing multiple blood transfusions, hemolytic anemia due to pyruvate kinase deficiency, Diamond Blackfan anemia) |
08 | Hydrocephalus | 06 Persons with congenital hydrocephalus with permanent artificial shunting of cerebrospinal fluid accompanied by other defects such as arachnoid cyst with epileptic seizure symptoms |
09 | Duchenne muscular dystrophy | 07 Persons suffering from Duchenne muscular dystrophy |
10 | Brainstem severe vascular malformation | 08 Persons suffering from brainstem severe vascular malformation |
11 | Malignant neoplasms | 09 Persons who have suffered in the past or suffer in the present from malignant neoplasms (leukemias, lymphomas, solid tumors) |
12 | Bund Chiari syndrome | 10 Persons suffering from Bund Chiari syndrome |
13 | Fabry disease | 11 Persons suffering from Fabry disease |
14 | Cystic fibrosis (of the pancreas or the lungs) | 12 Persons suffering from severe cystic fibrosis of the pancreas or the lungs |
15 | Multiple sclerosis | 13 Persons suffering from multiple sclerosis |
16 | Myasthenia gravis | 14 Persons suffering from myasthenia gravis for which they receive pharmaceutical treatment |
17 | Persons suffering from kidney failure receiving hemodialysis or peritoneal dialysis | 15 Persons suffering from chronic kidney failure treated with hemodialysis or peritoneal dialysis |
18 | Congenital bleeding diathesis – hemophilias | 16 Persons suffering from congenital bleeding diathesis – hemophilia treated with coagulation factors |
19 | Bone Marrow Transplantation | 17 Persons submitted to bone Marrow transplantation |
20 | Cornea transplantation | 18 Persons submitted to cornea transplantation |
21 | Heart transplantation | 19 Persons submitted to heart transplantation |
22 | Liver transplantation | 20 Persons submitted to liver transplantation |
23 | Lungs transplantation | 21 Persons submitted to lungs transplantation |
24 | Kidney transplantation | 22 Persons submitted to kidney transplantation |
25 | Pancreas transplantation | 23 Persons submitted to pancreas transplantation |
26 | Small bowel transplantation | 24 Persons submitted to small bowel transplantation |
27 | Juvenile diabetes (Type 1 diabetes) | 25 Persons suffering from insulin-dependent type 1 diabetes (juvenile diabetes) |
28 | Evans syndrome | 26 Persons suffering from Evans syndrome |
29 | Persons suffering from Mediterranean anemia/ Thalassemia major undergoing multiple blood transfusions | 05 Persons suffering from congenital hemolytic anemias undergoing blood transfusions or having severe clinical manifestations deemed disabled with a degree of disability of at least 67% (Mediterranean anemia/ Beta thalassemia/Thalassemia major, sickle cell anemia, micro-sickle cell anemia, persons suffering from Mediterranean anemia/ Beta thalassemia/Thalassemia major undergoing multiple blood transfusions, hemolytic anemia due to pyruvate kinase deficiency, Diamond Blackfan anemia) |
30 | Motor disabilities | 27 Persons with motor disabilities deemed disabled with a degree of disability of at least 67% |
31 | Phenylketonuria | 28 Persons suffering from phenylketonuria |
32 | Persons suffering from congenital thrombophilia receiving lifelong anticoagulation treatment | 29 Persons suffering from congenital thrombophilia receiving lifelong anticoagulation treatment |
33 | Arrhythmogenic right ventricular cardiomyopathy with implanted cardioverter-defibrillator | 30 Persons with arrhythmogenic right ventricular cardiomyopathy with implanted cardioverter-defibrillator |
34 | Gaucher disease | 31 Persons with Gaucher disease |
35 | Complex congenital heart diseases | 32 Persons suffering from complex congenital heart diseases operated or not |
36 | Single ventricle | |
37 | Truncus arteriosus communis | |
38 | Myocardial disease resulting in permanent malfunction | |
39 | Hypertrophic cardiomyopathy | 33 Persons suffering from hypertrophic cardiomyopathy |
40 | Pulmonary arterial hypertension | 34 Persons suffering from pulmonary arterial hypertension diagnosed by right heart catheterization |
41 | Severe pulmonary fibrosis | 35 Persons suffering from severe pulmonary fibrosis of any cause |
42 | Brugada syndrome | - |
43 | Idiopathic ventricular tachycardia | 36 Persons suffering from idiopathic ventricular tachycardia with implanted defibrillator |
44 | Glycogen storage diseases | 37 Persons suffering from glycogen storage diseases |
45 | Liver cirrhosis with portal hypertension | 38 Persons suffering from liver cirrhosis with attested portal hypertension |
46 | Portal hypertension due to portal vein hypoplasia | 39 Persons suffering from portal hypertension due to portal vein hypoplasia |
47 | Crohn’s disease | 40 Persons suffering from Crohn’s disease attested after biopsy |
48 | Wilson’s disease | 41 Persons suffering from Wilson’s disease |
49 | Multiple neurofibromatosis (Recklinghausen) | 42 Persons suffering from multiple neurofibromatosis syndrome (Recklinghausen) recurring systematically |
50 | Multiple myeloma | 43 Persons suffering from multiple myeloma |
51 | Sarcoidosis | 44 Persons suffering from sarcoidosis receiving major immunosuppressive therapy or having received major immunosuppressive therapy in the past and following a different pharmaceutical treatment related to this disease in the present due to lung or/and central nervous system infection |
52 | Autoimmune hepatitis | 45 Persons suffering from autoimmune hepatitis receiving major immunosuppressive therapy or having received major immunosuppressive therapy in the past and following a different pharmaceutical treatment related to this disease in the present. |
53 | Glomerulonephritis | 79 Persons suffering from glomerulonephritis receiving major immunosuppressive therapy (azathioprine, mycophenolic acid, cyclophosphamide, calcineurin inhibitors, rituximab) or high dosage of corticosteroids (Prednisone more than 0,5 mg/kg of body weight) |
54 | Total laryngectomy | 46 Persons submitted to total laryngectomy |
55 | Brain craniopharyngioma | 47 Persons suffering from brain craniopharyngioma |
56 | Systemic lupus erythematosus | 48 Persons suffering from systemic lupus erythematosus receiving major immunosuppressive therapy or having received major immunosuppressive therapy in the past and following a different pharmaceutical treatment in the present related to this disease due to kidneys or/and central nervous system or/and serous membranes or/and blood infection |
57 | Systemic scleroderma | 49 Persons suffering from systemic scleroderma with diffuse skin infection |
58 | Short bowel syndrome | 75 Persons suffering from short bowel syndrome |
59 | Ulcerative colitis under pharmaceutical treatment | 50 Persons suffering from ulcerative colitis receiving major immunosuppressive therapy or having received major immunosuppressive therapy in the past and following a different pharmaceutical treatment related to this disease in the present |
60 | Ulcerative colitis submitted to (procto)colectomy | 51 Persons suffering from ulcerative colitis submitted to total proctocolectomy and permanent ileostomy or subtotal colectomy with ileocolic anastomosis or created ileoanal pouch |
61 | Autoimmune thrombocytopenia | 52 Persons suffering from autoimmune hemolytic anemia or autoimmune thrombocytopenia receiving major immunosuppressive therapy |
62 | Juvenile idiopathic arthritis | 54 Persons suffering from continuously active juvenile idiopathic arthritis after the age of 14 years despite the biological treatment |
63 | Acquired immunodeficiency syndrome (AIDS) | 55 Persons suffering from acquired immunodeficiency syndrome (AIDS) under antiretroviral therapy |
64 | Paroxysmal nocturnal hemoglobinuria | 56 Persons suffering from paroxysmal nocturnal hemoglobinuria in need of chronic regular transfusions |
65 | Idiopathic thrombocytopenic purpura | - |
66 | Autoimmune hemolytic anemia | 52 Persons suffering from autoimmune hemolytic anemia or autoimmune thrombocytopenia receiving major immunosuppressive therapy |
67 | Klippel-Feil syndrome | 53 Persons suffering from the Klippel-Feil syndrome |
68 | Rare syndromes – diseases | 57 Persons suffering from various rare congenital, hereditary or acquired syndromes – diseases characterized by severe clinical manifestations deemed disabled with a degree of disability of at least 67%; to be examined on case-by-case basis |
69 | Klipper Trenaunay-Weber Syndrome | 58 Persons suffering from Klipper Trenaunay-Weber syndrome |
70 | Mucopolysaccharidoses Type 6 | 59 Persons suffering from mucopolysaccharidoses Type 6 |
71 | Dermatomyositis | 60 Persons suffering from dermatomyositis receiving major immunosuppressive therapy or having received major immunosuppressive therapy in the past and following a different pharmaceutical treatment in the present related to this disease |
72 | Muckle Wells syndrome | 61 Persons suffering from Muckle Wells syndrome (symptomatic disease with conventional clinical picture with a confirmed diagnosis by a pediatrician with experience in rheumatic diseases, genetic confirmatory testing for NALP3 cryopyrin mutation desired but not mandatory, since mutations are not attested in every patient, treatment with biological agents such as Interleukin IL-1 inhibitors) |
73 | Hereditary angioedema | 62 Persons suffering from laboratory confirmed severe hereditary angioedema |
74 | Benign pontine tumor | 63 Persons suffering from benign pontine tumor with a degree of disability of at least 67% |
75 | Aneurysm rupture with bleeding and hydrocephalus | 64 Persons suffering from aneurysm rupture with bleeding and hydrocephalus with a degree of disability of at least 67% |
76 | Congenital hemolytic anemia or Diamond Blackfan anemia | 05 Persons suffering from congenital hemolytic anemias undergoing blood transfusions or having severe clinical manifestations deemed disabled with a degree of disability of at least 67% (Mediterranean anemia/ Beta thalassemia/Thalassemia major, sickle cell anemia, micro-sickle cell anemia, persons suffering from Mediterranean anemia/ Beta thalassemia/Thalassemia major undergoing multiple blood transfusions, hemolytic anemia due to pyruvate kinase deficiency, Diamond Blackfan anemia) |
77 | Dyserythropoietic anemia | 65 Persons suffering from dyserythropoietic anemia confirmed with bone marrow biopsy and long-term need for transfusions |
78 | Tuberous sclerosis or Bourneville disease | 66 Persons suffering from tuberous sclerosis or Bourneville disease (phakomatosis of the central nervous system with various complications of the central nervous system, such as abnormal gait, difficulty with fine motor skills, concentration problems, fatigue etc) |
79 | Marfan syndrome | 67 Persons suffering from Marfan syndrome |
80 | Crouzon syndrome or craniofacial dysostosis | 68 Persons suffering from Crouzon syndrome or craniofacial dysostosis |
81 | Melorheostosis | 69 Persons suffering from melorheostosis with 80% degree of disability |
82 | Ichthyosiform erythroderma | 70 Persons suffering from ichthyosiform erythroderma with 67% degree of disability |
83 | Pharmacoresistant epilepsy | 71 Persons suffering from pharmacoresistant epilepsy with 67% degree of disability |
84 | Systemic mastocytosis | 72 Persons suffering from systemic mastocytosis confirmed with bone marrow biopsy and the level of tryptase in the blood |
85 | Kawasaki disease | 73 Persons suffering from Kawasaki disease along with coronary artery disease or giant coronary artery aneurysms |
86 | Lamellar ichthyosis | 74 Persons suffering from lamellar ichthyosis |
87 | Idiopathic nephrotic syndrome | 76 Persons suffering from idiopathic nephrotic syndrome receiving major immunosuppressive therapy at least one (1) year after the diagnosis (prednisone dosage of at least >0,5 mg/kg in combination with cyclophosphamide, calcineurin inhibitors, mycophenolic acid or biological agents such as rituximab) |
88 | Vasculitis/Angiitis | 77 Persons suffering from vasculitis/angiitis receiving biological therapy or major immunosuppressive therapy or having received major immunosuppressive therapy in the past following a different treatment in the present related to this disease |
89 | Severe congenital immunodeficiencies | 78 Persons suffering from severe congenital immunodeficiencies under immunoglobulin replacement therapy |
90 | Acquired Immunodeficiency Syndrome (Stage C) | 80 Persons suffering from acquired immunodeficiency syndrome (HIV Infection Stage C) under antiretroviral therapy on gravity level 3, that is with opportunistic infections: Pneumonia caused by Pneumocystis jiroveci, cerebral toxoplasmosis, fungal esophagitis, cryptosporidiosis, microsporidiosis, tuberculosis, infiltrative form of cervical cancer, Kaposi's sarcoma, lymphomas, neurocognitive disorders, pervasive mycobacterial disease, avium complex, cryptococcal meningitis, progressive multifocal leukoencephalopathy, wasting syndrome |
91 | Disability degree certified by a Disability Certification Centre (KEPA) | - |
92 | Learning disabilities [NKUA code] | - |
93 | ADHD (Attention-deficit/hyperactivity disorder) [NKUA code] | - |
94 | Pervasive neurodevelopmental disorders [NKUA code] | - |
95 | Psychological disorders [NKUA code] | - |